Summary
The provided text largely matches the supplied label excerpts for Sections 5.1, 5.2, and 6.1, but it also includes an extra meta/analysis block that is not part of the prescribing information and cannot be evaluated as label-aligned factual content.
Category Scores
Accurate Statements
Hostility- and aggression-related adverse reactions occurred more often with FYCOMPA (12% at 8 mg/day; 20% at 12 mg/day) than with placebo (6%); effects were dose-related and generally appeared within the first 6 weeks; serious, severe events led to dose reduction, interruption, and discontinuation more often than placebo.
Label excerpt Section 5.1
Neuropsychiatric events (irritability, aggression, anger, anxiety) occurred in ≥2% of FYCOMPA-treated patients and at twice the rate of placebo; other symptoms included belligerence, affect lability, agitation, and physical assault; some events were reported as serious and life-threatening.
Label excerpt Section 5.1
Homicidal ideation and/or threat occurred in 0.1% of 4,368 FYCOMPA-treated patients in controlled and open label trials (including non-epilepsy trials) and has been reported postmarketing.
Label excerpt Section 5.1
Patients should avoid alcohol because the combination of alcohol and FYCOMPA significantly worsened mood and increased anger.
Label excerpt Section 5.1 (and references Drug Interactions 7.3)
Patients should be monitored during treatment and for at least 1 month after the last dose; dose should be reduced if psychiatric symptoms occur; permanently discontinue for persistent severe or worsening psychiatric symptoms and refer for psychiatric evaluation.
Label excerpt Section 5.1
AEDs including FYCOMPA increase the risk of suicidal thoughts or behavior; monitor for emergence or worsening of depression, suicidal thoughts/behavior, and unusual changes in mood or behavior.
Label excerpt Section 5.2
Controlled clinical trials reported discontinuation rates due to adverse reactions by dose (3% at 4 mg, 8% at 8 mg, 19% at 12 mg) versus 5% with placebo; common adverse reactions leading to discontinuation included aggression and anger (and irritability).
Label excerpt Section 6.1
Unsupported Statements
The appended 'LABEL ASSESSMENT' and internal claims such as 'Supported: yes' / 'Contradicted: no' / 'Evidence Summary' / 'final_verdict' are asserted as conclusions without being part of the prescribing information itself.
These are meta-evaluative statements and are not supported or verifiable as label content from the provided excerpts.
Contradictions
Important Omissions
No clear omission of label-supported content relative to the psychiatric/suicidality/behavioral warnings described; however, the dosage category alignment is reduced because the text is more comprehensive about warnings than it is about complete dosage-and-administration instructions (the label excerpt focuses on warnings/precautions rather than full dosing regimen).
Importance:
Minor
Safety Assessment
Potential Patient Risk:
Low
The substantive statements provided align with the label excerpts describing psychiatric/behavioral risks, suicidal ideation/behavior risk, monitoring guidance, and dose-related discontinuation context; the main misalignment is presence of non-label meta assessment content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Includes non-prescribing-information meta 'LABEL ASSESSMENT' content that is not label-supported factual drug information.
Suggested Improvement
Limit output to label-derived prescribing information content (e.g., Warnings and Precautions 5.1/5.2 and adverse reaction/discontinuation details in 6.1), and remove internal meta-evaluation sections.